Core Insights - Lu Kang Pharmaceutical has focused on cultivating growth-oriented subsidiaries as a key strategic initiative to enhance innovation and core competitiveness over the past decade [1] - By 2024, the revenue of growth-oriented subsidiaries is expected to increase by 150% compared to 2018, becoming a significant driver of the company's development [1] Group 1: Strategic Focus - The company has identified "strategy + support + supervision" as three key areas to accelerate the development of subsidiaries, positioning various companies in specific leadership roles within their respective markets [2] - The company aims to strengthen supervision and support for growth-oriented subsidiaries, guiding them to establish modern corporate systems and new business models [2] Group 2: Transformation Initiatives - Lu Kang Pharmaceutical promotes six transformations for its growth-oriented subsidiaries, including transitioning from small to large enterprises and shifting focus from production to R&D and sales [3] - The largest subsidiary, She Li Le, has established a comprehensive system for research, production, and sales, ranking 14th globally among animal health companies in 2024 [3] Group 3: Support Models - The company implements a new support model characterized by precision, personalization, order-based assistance, and quantifiable indicators to enhance subsidiary development [4] - Five main lines of management are proposed to address bottlenecks in subsidiary development, ensuring comprehensive oversight in various operational aspects [4] Group 4: Performance Outcomes - Under the growth-oriented subsidiary strategy, significant achievements have been made, with sales revenue for Sai Te expected to double by 2024 compared to 2014 [5] - Qinghai Lu Kang Da Di is projected to see a 1.5 times increase in sales revenue by 2024 compared to 2014, while the biological pesticide segment anticipates a threefold revenue increase [5]